Browse News
Filter News
Found 172 articles
-
Merck KGaA, Darmstadt, Germany, Enters Two Strategic Collaborations to Strengthen AI-driven Drug Discovery
9/20/2023
Merck KGaA, Darmstadt, Germany, a leading science and technology company, announced two new strategic drug discovery collaborations aimed at harnessing powerful artificial intelligence -driven design and discovery capabilities, further advancing the company’s research efforts.
-
Exscientia Announces AI Drug Discovery Collaboration with Merck KGaA, Darmstadt, Germany
9/20/2023
Exscientia plc announced a new collaboration with Merck KGaA, Darmstadt, Germany focused on the discovery of novel small molecule drug candidates across oncology, neuroinflammation and immunology.
-
Exscientia to Present at Upcoming Investor Conferences in September 2023
8/31/2023
Exscientia plc announced that members of Exscientia management will participate in the following upcoming investor conferences in September: 2023 Wells Fargo Healthcare Conference.
-
Precision Oncology Market Size is Projected to Reach USD 2,58,350 Million By 2032
8/17/2023
The global precision oncology market size is estimated to grow from USD 1,00,060 million in 2022 to reach around USD 2,58,350 million by 2032, growing at a CAGR of 9.9% from 2023 to 2032, A study published by Towards Healthcare.
-
Exscientia Business Update for Second Quarter and First Half of 2023
8/10/2023
Recent advancements in the Company’s pipeline, collaborations and operations, as well as financial results for the second quarter and first half 2023, are summarised below. Exscientia will host a conference call Thursday, August 10 at 1:30 p.m. BST / 8:30 a.m. EDT.
-
Exscientia to Report Second Quarter 2023 Financial Results on August 10, 2023
8/3/2023
Exscientia plc (Nasdaq: EXAI) will report financial results for the second quarter ended June 30, 2023, on Thursday August 10, 2023, before the open of U.S. markets.
-
Exscientia Initiates Prospective Observational Study in Ovarian Cancer
7/18/2023
Exscientia plc (Nasdaq: EXAI) today announced the initiation of EXCYTE-1, a prospective observational study in ovarian cancer to investigate the relationship between ex vivo drug response (EVDR) in primary tumour-derived samples using the company’s precision medicine platform and actual patient clinical response.
-
First Patient Enrolled in Phase 1/2 “ELUCIDATE” Trial Assessing GTAEXS617 in Advanced Solid Tumours
7/10/2023
Exscientia plc (Nasdaq: EXAI) today announced that it has enrolled the first patient in its Phase 1/2 “ELUCIDATE” (GTAEXS617-001) study evaluating GTAEXS617 (‘617), Exscientia’s precision-designed CDK7 inhibitor, for the treatment of advanced solid tumours.
-
Exscientia Announces Expansion of its Technology Leadership Team
6/29/2023
Exscientia plc (Nasdaq: EXAI) announced today that it is expanding its technology management structure to accelerate application of Exscientia's innovative technologies to catalyse instrumental change in the way drug candidates are being discovered, designed and developed for patients in need of innovative therapies.
-
Exscientia to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
6/6/2023
Exscientia plc (Nasdaq: EXAI) today announced that members of Exscientia management will participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference on Tuesday, June 13, 2023, at 11:20 a.m. PDT (7:20 p.m. BST).
-
AI Proteins Announces the Formation of a Scientific Advisory Board Made up of Experts in Biotech and FDA Drug Approval
5/31/2023
AI Proteins, Inc., a growing biotechnology company that utilizes computational de novo protein design to create novel therapeutic miniproteins, today announced the formation of a Scientific Advisory Board.
-
Exscientia Business Update for First Quarter 2023
5/24/2023
Recent advancements in the Company’s pipeline, collaborations and operations, as well as financial results for the first quarter 2023, are summarised below. Exscientia will host a conference call Wednesday, May 24 at 1:30 p.m. BST / 8:30 a.m. EDT.
-
Exscientia Highlights "The Future of AI-enabled Drug Discovery" at SLAS Europe
5/22/2023
Exscientia plc (Nasdaq: EXAI) today announced two abstracts for oral and poster presentation, as well as the closing keynote to be delivered at the Society for Laboratory Automation and Screening (SLAS) Europe Conference and Exhibition being held May 22-26, 2023, in Brussels, Belgium.
-
New Clarivate Biopharma Dealmaking Report Reveals Investment Patterns Set to Impact the Future of Medicine
5/17/2023
Clarivate Plc, a global leader in connecting people and organizations to intelligence they can trust to transform their world, released its new report, Biopharma Dealmaking in 2023.
-
Exscientia to Report First Quarter 2023 Financial Results on May 24, 2023
5/17/2023
Exscientia plc (Nasdaq: EXAI) will report financial results for the first quarter ended March 31, 2023, on Wednesday, May 24, 2023, before the open of U.S. markets.
-
Exscientia Announces Sixth Molecule Created Through Generative AI Platform to Enter Clinical Stage
5/15/2023
Exscientia plc announced that Sumitomo Pharma Co., Ltd. plans to initiate a Phase 1 clinical study of DSP-2342 in the United States.
-
The pharma company will lay off 170 employees and drop all candidates but one, as it seeks to rebuild its business.
-
Exscientia Appoints Harvard Professor Franziska Michor, Ph.D. to Board of Directors
5/3/2023
Exscientia plc (Nasdaq: EXAI) today announced the appointment of Professor Franziska Michor, Ph.D. to its Board of Directors.
-
Data Presented at AACR 2023 Highlights Exscientia’s Clinical and Preclinical Development
4/19/2023
Exscientia plc (Nasdaq: EXAI) today announced four presentations at the American Association for Cancer Research (AACR) Annual Meeting 2023, being held from April 14-19, 2023 in Orlando, FL.
-
Captor Therapeutics Discloses Molecular Targets of Pipeline’s Lead Assets and Invites Stakeholders to Webcast
3/28/2023
Captor Therapeutics S.A. discloses the identity of the drug targets as well as associated supporting data, and provides an update on the progress in the research and development of its pipeline lead programs CT-01, CT-02 and CT-05.